The company said the results demonstrated exparel "significantly improved pain control and reduced opioid consumption" through 48 hours compared with placebo and a "standardized" pain management protocol alone.
A total of 140 patients enrolled across 16 surgical centers in the US, Belgium, and Denmark were randomized to receive an ultrasound-guided single-dose ISNB with either exparel 133 mg (n=69) or saline placebo (n=71).
"Results from this study illustrate the clinical effectiveness of an interscalene brachial plexus nerve block with exparel, which provides prolonged pain control in a single dose without the need for additional equipment," said Manish Patel, an investigator in the study.
Price: 42.52, Change: -0.99, Percent Change: -2.28
|Analysts' Decrease 2019, 2020 Consensus Estimates fo...|
|2019, 2020, and Q2 Earnings Estimates for Exxon Mobi...|
|2019 Estimate for YIT Oyj Scaled Up but 2020 Earning...|
|Watsco's 2019, 2020, and Q3 Earnings Estimates Reduced|
|Westlake Chemical's Q2, 2019, and 2020 Earnings Redu...|